ImmuneOnco Doses First Patient in Tumor Drug Study
MT Newswires Live
Oct 23
ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) dosed the first patient in a phase IB/II clinical trial of IMM2510, a Thursday Hong Kong bourse filing said.
The trial is testing the drug in combination with IMM01 for the treatment of advance solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.